Thakkar, N
Gonzalez, D
Cohen-Wolkowiez, M
Massaro, M M
Bernhardt, J
Zane, N R
Laughon, M M
Article History
Received: 18 November 2015
Revised: 23 March 2016
Accepted: 1 April 2016
First Online: 12 May 2016
Competing interests
: DG receives research support through 1K23HD083465-01 from the National Institute of Child Health and Human Development (NICHD) and from the nonprofit organization Thrasher Research Fund (ExternalRef removed). MC-W receives support for research from the National Institutes of Health (NIH) (1R01-HD076676-01A1), the National Center for Advancing Translational Sciences of the NIH (UL1TR001117), the National Institute of Allergy and Infectious Diseases (HHSN272201500006I and HHSN272201300017I), the NICHD (HHSN275201000003I), the Food and Drug Administration (1U01FD004858-01), the Biomedical Advanced Research and Development Authority (HHSO100201300009C), the nonprofit organization Thrasher Research Fund (ExternalRef removed) and from industry (CardioDx and Durata Therapeutics) for drug development in adults and children (ExternalRef removed). MML receives support from the US government for work in neonatal clinical pharmacology (National Heart, Lung and Blood Institute: R34 HL124038: PI, Laughon; Pediatric Trials Network: Government Contract HHSN267200700051C, PI: Benjamin; and NICHD: 1K23HL092225, PI: Laughon), as the satellite site PI for the NICHD Neonatal Research Network (5U10HD040492, PI: Cotten) and from industry for drug development or member of data safety monitoring boards (Abbvie, Astellas Pharma, Pfizer and MediPost). All other authors declare no conflict of interest.